Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027

Acumen Pharmaceuticals ( (ABOS) ) has shared an update.

On March 26, 2026, Acumen Pharmaceuticals reported full-year 2025 results and updated investors on progress in its Alzheimer’s pipeline, highlighting ongoing Phase 2 development of sabirnetug and expansion of its Enhanced Brain Delivery platform. The company also refreshed its corporate presentation to reflect year-end 2025 cash of $116.9 million and a $35.75 million private placement completed on March 16, 2026, extending its cash runway into early 2027.

During 2025 the company increased R&D spend to $104.9 million, driving a larger net loss of $121.3 million, as it funded the ALTITUDE-AD trial, EBD research and manufacturing scale-up. Operationally, Acumen dosed the first patient in the open-label extension of ALTITUDE-AD in November 2025 and presented new data at key neurology conferences, while guiding that Phase 2 topline results are expected in late 2026 and an IND for its EBD lead candidate is targeted for mid-2027.

The most recent analyst rating on (ABOS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Acumen Pharmaceuticals stock, see the ABOS Stock Forecast page.

Spark’s Take on ABOS Stock

According to Spark, TipRanks’ AI Analyst, ABOS is a Neutral.

The score is held back primarily by weak financial performance (no revenue, widening losses, and worsening cash burn that elevates dilution risk). This is partially offset by a constructive earnings-call outlook (clear clinical milestones and cash runway into early 2027) and supportive technical trend, though momentum appears overbought. Valuation signals are limited due to negative earnings and no dividend yield.

To see Spark’s full report on ABOS stock, click here.

More about Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease. Its lead candidate, sabirnetug (ACU193), a humanized monoclonal antibody granted Fast Track designation in the U.S., is being evaluated in the Phase 2 ALTITUDE-AD trial, alongside work on subcutaneous delivery and an Enhanced Brain Delivery program with JCR Pharmaceuticals.

Average Trading Volume: 828,934

Technical Sentiment Signal: Buy

Current Market Cap: $159.3M

For a thorough assessment of ABOS stock, go to TipRanks’ Stock Analysis page.